The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 OSI Pharmaceuticals Inc.  (OSIP) Trade Now »     Rate OSIP  -  Discuss OSIP  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
This is a micro-cap stock and may be a target of manipulation. Always do your research!

SocialPicks Sentiment:
N/A

** not enough data to be rated 		This Quarter's Sentiment:
All:
90.0%
Top:
100.0%
Rate OSIP:



OSIP Analysis & Videos »


OSIP: Bull or Bear?

FDA, Clinical Trial News: Approvals for OSI and Par Pharma Graphic_rating_buy OSIP
Mikerun
73%
Late Friday evening, OSI Pharma (NASDAQ:OSIP) announced FDA approval to expand the use of Tarceva (erlotinib) as a maintenance treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. <> <font> Shares of OSIP closed regular trading today at $59.52 with a market cap of $3.5 billion, well above the hostile bid of $52 per share announced in early March by Astellas Pharma (ALPMY.PK) that represented a 40% premium at the time the deal was originally announced with t...
By  Mike Havrilla   (+1.04%  risk: moderate)  04/17/10 35 comments


Updated Clinical Trial and FDA Decision Calendars Graphic_rating_buy OSIP
Mikerun
73%
Below is a summary of updates to the BioMedReports.com database of 241 entries included in the FDA and Clinical Trial Calendars.
 
 
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 104 entries through 3/20/09. The FDA Calendar includes the following information: company name, ticker, decision date, and descrip...
By  Mike Havrilla   (+1.04%  risk: moderate)  03/20/09 10 comments


OSI Pharmaceuticals Inc. Graphic_rating_buy OSIP
Foto
62%
OSI Pharmaceuticals, Inc., a biotechnology company, discovers, develops, and commercializes molecular targeted therapies for oncology, diabetes, and obesity in the United States and internationally. Its flagship product, Tarceva (erlotinib) is a small molecule inhibitor of the epidermal growth factor receptor, which is used for the treatment of advanced non-small cell lung cancer, as well as for the treatment of patients with locally advanced and metastatic pancreatic cancer in combination with the chemotherapy agent, gemcitabine. The company also offers Macugen for the treatment of neovasc...
By  Marian Filo   (-24.55%  risk: aggressive)  09/01/08 3 comments


Get free stock alert for OSIP:
Your Email Address:





People Bullish on OSIP

Mikerun
Mike Havrilla
Principal
73%
over 2 years ago

daxpd28
Analyst
82%
over 3 years ago

Foto
Marian Filo
Principal
62%
over 3 years ago

Images
amob05
Sr. Analyst
21%
over 4 years ago


People Bearish on OSIP

ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.36% 531
2 Gerald Greene 18.14 +36.28% 286
3 stockmarketfunding.com 17.66 +23.07% 83
4 akiralegrand 13.47 +13.37% 69
5 anup2104 12.13 +132.16% 102


POPULAR STOCKS
Symbol Company Name Sentiment
CAT Caterpillar Inc
RIMM Research in Motion Ltd
MA MasterCard Inc
C Citigroup Inc
MO Altria Group Inc
RIO Companhia Vale Do Rio Doce

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on OSIP


Discussion Wall + Add  

Be the first to start a discussion and earn 2 points.



More Resources

Graphic_arrow1 About OSI Pharmaceuticals Inc. - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch